跳至主要内容
临床试验/NCT06472271
NCT06472271招募中不适用

Colistin in Neonatal ICU Patients With Gram Negative Resistant Infection: Dosage Personalization Approach

Mahmoud I Mostafa1 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2024年7月30日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
100
试验地点
1
主要终点
Clinical response

研究概览

简要总结

A few studies have evaluated higher doses or the administration or a loading dose, which is routine in adults, in pediatric patients, and reported improved colistin exposure without an increased risk of nephrotoxicity The main questions it aims to answer are What is the optimal dosing strategies of intravenous colistin for the treatment of multidrug-resistant gram-negative bacterial infections in preterm neonates? What is the incidence of AKI? What is the factors increasing AKI incidence? A single center retrospective and comparative study, cohort study compare low dose 5 mg/kg/day versus 7.5mg/kg/day

详细描述

Retrospective study to measure safety and efficacy of colistin conventional dose versus high dose then prospective design to measure pharmacokinetics parameter of both doses to design optimal dose

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Other

入排标准

年龄范围
0 Days 至 28 Days(Child)
性别
All
接受健康志愿者

入选标准

  • Neonates aged between (0-30 days) born before 37 weeks
  • Critically ill patients with nosocomial infection with proven culture-resistant gram-negative bacteria.
  • Neonates who are indicated for colistin and started colistin therapy for at least 48 hr.

排除标准

  • Serum creatinine ≥1.5 baseline before colistin
  • Received colistin before NICU stay
  • Administration of concurrent nephrotoxic drugs including amphotericin, gentamicin, or amikacin.
  • Major congenital anomalies or with previous renal impairment.

研究组 & 干预措施

Conventional initial dose

Colistin 5mg/kg/day

干预措施: Polymyxin e (Drug)

High initial dose

Colistin 7.5mg/kg/day

干预措施: Polymyxin e (Drug)

结局指标

主要结局

Clinical response

时间窗: 21 days

Resolving signs and symptoms with normalized acute phase reactants in clinical septic patients

次要结局

  • Microbiological clearance(21 days)

研究者

发起方
Mahmoud I Mostafa
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Mahmoud I Mostafa

Lecturer at pharmacy practice department

Helwan University

研究点 (1)

Loading locations...

相似试验